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Introduction
During recent years, the field of innate immunity has exploded, particularly since the dis-
covery of Toll-like receptors. It suddenly became evident to many immunologists that the
initial inflammation induced by microorganisms was an essential trigger factor of the more
elaborate specific immunity. The initial response is pattern recognition, whether on cell
surfaces, as for Toll-like receptors, or in the fluid phase, as for complement and natural
antibodies. Complement activation in the innate immune response is due to natural IgM
antibodies and CRP, but is also directly due to mannan-binding lectin (protein) and depo-
sition of C3 by the alternative pathway. Once acquired immunity has allowed the production
of specific antibodies, complement again comes into play via the first recognized pathway
of complement—the classical activation pathway—which occurs when C1q binds to the
antigen–antibody complex. During ontogeny, the roles of protection against intruders and
disposal of waste developed in parallel. In particular, apoptotic and necrotic cells have to
be cleared. It is therefore not surprising that innate immunity, complement in particular, is
also involved in helping to remove waste.
The knowledge gained in the field of complement has exploded in recent years, and this
issue makes no claim to cover the topic completely. Rather, it is a selection of those fields in
which there has been a development that might interest not only the immunologist but also
the clinician who wants to understand more about specific aspects of diseases in which
complement plays a central role.
The first complement deficiency to be identified was C1 inhibitor deficiency, although we
now recognize that the clinical syndrome of angioedema is related to the inhibition of the
kinin cascade by C1 inhibitor and not to its capacity to control the complement cascade. If we
had to give a name to this molecule today, we might consider “kinin inhibitor” as more
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logical for clinicians, who first of all consider the pathophysiology of a disease. Cicardi
reviews the field from basic knowledge about the immunopathological processes to the
clinical aspects and indicates possible future treatment options. And the future appears to be
near.
Anti-C1q autoantibodies were described initially by Agnello more than 30 years ago.
Understanding of their role was hampered initially because C1q binds to IgG, and thus, the
reverse reaction had to be indisputably established before the scientific world would accept
the finding. Subsequently, the groups of Daha and Mannik established that such auto-
antibodies were frequently found in SLE, specifically in lupus nephritis, and were deposited
in the kidney. This field is in development, and the finding that C1q deficiency (also
knockout in mice) leads to an SLE-like disease underlines the major role of the C1q protein in
SLE. Marten Trendelenburg takes us through the recent literature concerning antiC1q.
During the past decade, David Sacks has investigated the role of local synthesis of
complement proteins in kidney diseases and, in particular, in renal transplantation. He has
recently demonstrated the role of locally produced C3 in regulating alloreactivity and organ
rejection. His article is a very thorough overview of the fascinating subject of renal pro-
duction of complement.
The next article by Véronique Frémeaux-Bacchi deals with the hemolytic uremic syn-
drome (HUS) and complement abnormalities. The developments in this field in recent years
have been fascinating, with the demonstration that specific mutations of factor H are
associated with HUS, but also that MCP contributes to the protection against this devastating
disease. The suggestion that factor I mutation can lead to HUS, as well as the finding in some
rare cases that anti-factor H autoantibodies may be involved, provides additional support for
the hypothesis that proper control of the alternative pathway is essential for protecting the
renal glomerular endothelial cells against injury.
John Atkinson reviews the multiple aspects of “membrane cofactor protein” (MCP),
which he calls CD46 in the title of his article. This is certainly due to the multiple aspects
of MCP which are not directly related to its complement control activity, e.g., its interaction
with many human pathogens or its role in inducing T-lymphocyte regulatory cells. This
molecule first described by complementologists appears to have more facets than originally
expected.
Following the description of mannan-binding lectin (MBP) many years ago, there has
been much activity aimed at finding out how this protein activates the complement cascade.
Many investigators successively described different “mannan-binding protein associated
proteases” (MASPs), one of which—MASP2—emerged as the most likely protease linking
MBP to cleavage of C4 and C2. In this respect, the review of Rikke Sorensen and colleagues
is timely, not only to describe the biochemistry of MASP2 but also for its possible role
in preventing infection and autoimmunity, as suggested by the diseases associated with
MASP2 deficiency in a unique patient.
Parasites appear to be capable, when it suits them, of stealing fragments of the human
genome, for example, when the stolen fragment allows them to produce an inhibitor of
complement activation. Indeed, the expression of a complement inhibitor may be protective
for parasites, such as schistosomes, which live in the blood stream. Jameel Inal speculates
on such a horizontal gene transfer for complement C2 receptor inhibitor trispanning (CRIT),
a molecule he first found in schistosomes, then in trypanosomes, and finally in humans.
In the final article, David Pilzer and colleagues come back to a well-known phenomenon,
i.e., the release of small vesicles by ectocytosis from cells which have been attacked by
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complement. These small vesicles remove the membrane attack complex from the cell
surface, thereby protecting the cell. On the other hand, the biology of ectosomes has only
recently attracted the interest of biologists. These small vesicles have functions such as
release of mediators, transfer of information from one cell to another, and modulating in-
flammation and thrombosis.
It has been a privilege to bring together these different contributions, thanks to a won-
derful group of investigators and friends. We thank them all and hope that the reviews
provided will be helpful for clinicians and scientists alike. Finally, our thanks to Mrs. Jean
Ringrose, who helped us to bring these reviews together in her very gentle way.
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